LAUSR

IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 – Opening ceremony Abstracts # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 OP1 INCLUSION OF DIVERSITY IN SCIENCE S. Brennan-Olsen 1 University of Melbourne, Department of Medicine-Western Health and Australian Institute for Musculoskeletal Science (AIMSS), Melbourne, Australia Objective: Current efforts to promote diversity in science are predominantly focused on the undeniable importance of gender equity, but conscious efforts are necessary to remove unintentional bias that excludes of other forms of diversity. This session discusses how multicultural, ability and demographic diversity in conference representation, research teams, committees and working parties will enhance the radicalness of scientific innovation and have a higher absorptive capacity to exploit external knowledge. Method: Based on a narrative review of published and grey literature, this discussion focuses on the barriers to achieving, and strategies to enhance, diversity in science. Results:Barriers to inclusiveness of diversity include unconscious bias in vocabulary, policies and processes. Based on concrete efforts to achieve gender equity in science, strategies to achieve multicultural, ability and demographic diversity may fall into one or more categories of: 1) remove obstacles, 2) increase capacity, 3) change culture, and/or 4) advocate. Efforts to remove obstacles include the development and/ or amendment of Speaker Policies that demonstrate commitment to diversity in speaker composition and thus quality in conversation. Improving diversity at management level, and initiatives that provide specific funding opportunities could increase capacity. Strategies aimed at changing culture focus on ‘fixing workplaces’ rather than attempts to ‘fix individuals’, whilst advocacy must swell across the world, similar as the current movement observed in terms of gender equity. Conclusion: Diversity is consistent with high-quality conference programs, research teams, committees and working parties. Providing equity of opportunities for all scientists is achievable by conscious consideration of unconscious bias. Disclosures: SLB-O is supported a NHMRC, Australia, Career Development Fellowship and received speaker fees from Amgen Australia and Pfizer Australia. OP2 OSTEOPOROSIS: GLOBAL CHALLENGES, LOCAL IMPACTS L. M. March 1 Surveillance Task Force for the Global Alliance for Musculoskeletal Health; University of Sydney Institute of Bone and Joint Research, Kolling Institute; Department of Rheumatology Royal North Shore Hospital, St Leonards, Australia Aim: The global and local challenges of osteoporosis are numerous. This paper will outline the key challenges and introduce some new concepts to dispel the myth that osteoporotic fractures only follow minimal trauma. Local solutions for preventing the next fracture will be described. Methods: An overview of the epidemiological literature for fracture and osteoporosis prevalence, including analyses from the Global Burden of Diseases (GBD) and uptake of re-fracture prevention programs described. Results: A key challenge is that osteoporosis (OP) and related fractures are yet to be identified as a disease in their own right. This limits data collection in any national or global burden of diseases study – if a health condition isn’t defined by an ICD code it doesn’t exist. “No datano disease”. Osteoporosis has been defined by low bone mineral density, but also by the presence of a low or minimal trauma fracture in people over 50 years of age. While low BMD is a very strong predictor for having a fracture there are numerous other factors that contribute to fracture risk and many fractures will occur in the presence of normal or only mildly reduced BMD. Osteoporosis and risk of fracture increases significantly with age and as such often attracts low interest as an inevitable association with ageing for which nothing can be done. With the rise in the ageing population, the prevalence of people living in the community with low BMD, and thus at risk of having a fracture, is also rising. This is particularly evident in the Asian-Pacific region. Osteoporosis is a silent disease until a person sustains a fracture. That first fracture is a significant risk factor for a subsequent fracture. Medications are available that can significantly reduce the risk of subsequent fractures yet these are not being introduced to people who may benefit. For the past two decades we have been discussing this evidence-care-gap. Local, national and international audits lamenting the lack of identification, assessment and treatment of OP fracture to prevent the next fracture abound. Multiple barriers at all levels have been identified from the individual, to the full range of health professionals involved in theOP fracture care and to the health system and society as a whole. Qualitative research reveals that people with OP do not associate fractures with low bone density and do not perceive themselves to be at risk. Lifestyle interventions, while important, are insufficient alone for reducing the increased risk of secondary fractures. Medications, while effective, are not without risk of adverse events. It is estimated that there are more than 200 million women globally with low BMD and that 1 in 2 to 3 women and 1 in 5 men over the age of 50 years will experience an osteoporotic fracture in their life time. Currently in Asia over 1 million hip fractures occur each year with an estimated 2.5 million in 30 years predominantly attributable to ageing and growing populations in China and India. By 2050 it is estimated that 50% of the world’s hip fractures would come from Asia. In the Global Burden Osteoporosis International (2019) 30 (Suppl 1):S35–S36 https://doi.org/10.1007/s00198-018-04808-4